ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) (TSE:EPI) major shareholder Growth N. V. Biotech sold 7,879,583 shares of ESSA Pharma stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $1.53, for a total value of $12,055,761.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
ESSA Pharma Price Performance
Shares of EPIX opened at $1.70 on Wednesday. The company has a 50-day simple moving average of $5.74 and a two-hundred day simple moving average of $5.61. The firm has a market capitalization of $75.43 million, a PE ratio of -2.74 and a beta of 1.84. ESSA Pharma Inc. has a one year low of $1.40 and a one year high of $11.67.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) (TSE:EPI) last released its earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.10. Analysts expect that ESSA Pharma Inc. will post -0.71 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Download Our Tesla Ebook For Free
From DTI | Ad
Like many of you, we here at the TradingPub are bullish on Tesla long term.
We believe the company will continue to be a leader in technology, EVs and A.I.
We also believe it’s share price will be rewarded in a big way…
In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
To claim your copy free of charge simply follow this link.
Several research analysts recently commented on EPIX shares. Oppenheimer downgraded shares of ESSA Pharma from an "outperform" rating to a "market perform" rating in a research note on Monday. Piper Sandler cut ESSA Pharma from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $15.00 to $2.00 in a research note on Monday. Finally, Jefferies Financial Group lowered ESSA Pharma from a "buy" rating to a "hold" rating in a research note on Monday.
Read Our Latest Report on ESSA Pharma
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in ESSA Pharma stock. EntryPoint Capital LLC purchased a new stake in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) (TSE:EPI) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,420 shares of the company's stock, valued at approximately $38,000. Institutional investors own 75.12% of the company's stock.
About ESSA Pharma
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
